



How to Make Control-IQ Technology Adjustments Using Tandem Source

Tandem Source	Reports		? 🗉	
Patient List	< Patient List			
<u>↑</u> Upload Pump	Tom Tandem Last Upload: Jun 23, 5:31 PM   tislim X2 (Control-I Overview Daily Timeline Pur	Q) 19 Settings	¢.	
	2 Weeks (Jun 10 - Jun 23) 👻		CGM Data by [CGM Provider]	
	CGM summary	ime in range comparison	Control-IQ summary	
		Current 2 weeks Previous 2 weeks	Time active 98 % 13 d 4 hrs Control-IQ off 0 % 0 hrs	
	Time in range 86 % Time CGM in use 100 %	0% > 250 0% 13% 181 - 250 14%	CGM inactive 1% 2 hrs	
	Standard deviation 37 mg/dL	86% In Range 85%	Pump inactive 1% 4 hrs	
	Coefficient of variation 28 %	86% 70 - 180 85%	Average sleep Average exercise	
	GMI Requires 2 weeks/70% CGM use	0% 54 - 69 0% < 54 - 0% -	Duration 9 hrs Duration 0 hrs Weekly 7 times Weekly 0 times	
	Glucose trends			
			400	
	The second secon	and the second	180	
		Management and M	70 jp	
	12 AM 2 4 6 AM 8	10 12 PM 2 4	6 PM 8 10 11:59	
	Insulin summary	Bolus review (daily average)	Load activity	T:30 AM I B
		ype cod 73 % 11.90 u	Cartridge change every 7.0 d	◆ 4400 4400 4400 400 400 400 mg/dL
		cod         73 %         11.90 u           Correction         7 %         1.07 u	Tubing fill every 7.0 d Cannula fill every -d	< 250 J
			Cambia nii every -a	150 3 100 HRS
				INSULIN ON BOARD 2.2 u BOLUS •• 50 Control-10: 0.80 u

## Instructions for Use



View User's Pump Data

Visit **source.tandemdiabetes.com** and upload pump data or view reports.




## Save and Print Reports


Select Overview, Daily Timeline, and Pump Settings at last upload, and select a two week date range.

~	
~	
~	

## Follow the Worksheet

Get step-by-step guidance on clinical assessment, user education, and insulin dose adjustments.





Average daily dose		30.29 u
Basal	46 %	14.03 u
olus	54 %	16.26 u
Average daily boluses		8 boluses
<i>I</i> anual	61%	5 boluses
Control-IQ	39 %	3 boluses
Average daily carbs		<b>96</b> g

Туре		
Food	73 %	11.90 u
Correction	7 %	1.07 u
Override	4 %	0.63 u
Control-IQ	16 %	2.66 u
Delivery Method		
Standard	82 %	13.26 u
Extended	0 %	0.00 u
Quick	2 %	0.34 u
Control-IQ	16 %	2.66 u

Cartridge change	every	7.0
Tubing fill	every	7.0
Cannula fill	every	- (

CGM Data by	(CGM Provider)
-------------	----------------

Control-IC	) summar	y	
Time active		<b>98</b> %	13d 4hrs
Control-IQ off		0 %	0 hrs
CGM inactive		1%	2 hrs
Pump inactive		1 %	4 hrs
Zz	z	=3	e
Average	e sleep	Average	exercise
Duration	9 hrs	Duration	0 hrs
Weekly	7 times	Weekly	0 times

A	В
Are glycemic targets being met? <sup>1</sup>	Is Control-IQ technology being used?
<b>Level 2 hypoglycemia:</b> Time Below Range (TBR) <54 mg/dL, goal is <1%	Time Control-IQ in use (Percent of time that Control-IQ technology is in use): Aim for >90%. If less, assess why.
<b>Level 1 hypoglycemia:</b> TBR 54-69 mg/dL, goal is <4%	<b>CGM inactive (Time sensor not active):</b> Aim for <10%. If
<b>Time in range (TIR):</b> 70-180 mg/dL, goal is >70%	more, assess why. <b>Daily sleep:</b> Recommended

Patterns

Level 1 hyperglycemia: Time Above Range (TAR) 181-250 mg/dL, goal is <25%

Level 2 hyperglycemia: TAR >250 mg/dL, goal is <5%

## **ise):** Aim for >90%. assess why. inactive (Time or not active): or <10%. If assess why.

sleep: nmended to program Sleep Schedule.

Weekly exercise events: Assess use of Exercise Activity

and outcomes.

Content adapted with permission from the PANTHER Program,<sup>®</sup> University of Colorado, pantherprogram.org

C	D
Are there patterns of hypoglycemia and/ or hyperglycemia?	Assess insulin delivery

Use Glucose trends to understand average glucose data throughout the day. Assess and identify glycemic trends throughout the morning, afternoon, evening, and overnight. Focus on the areas where the average glucose is out of target range.

The median line (where half of the alucose values are above and half are below) should ideally be mostly flat and within the target range of 70-180 mg/dL.

25/75% shows 50% of the glucose values; ideally, shaded area is narrow.

10/90% shows where 10% of values are below (bottom dotted lined) and 10% are above (top dotted line); ideally the closer the dotted lines are to the darker shaded area, the better.


Ratio of basal to bolus delivery: Basal percentage typically between 40-60%<sup>2</sup>


If not, assess why (activity level, bolus behaviors, types of meals, increased interaction with system).

Consider verifying user's settings: See back of handout for instructions on how to calculate.

Types of boluses: Assess types of meals/ timing of bolus, carb counting knowledge, and carb ratios.







## Identify the predominant causes of a hypoglycemia or hyperglycemia pattern

## Is a hypoglycemia pattern occurring?

- Fasting/overnight?
- ✓ After meal bolus? (1-3 hours after)
- Following hyperglycemia events?
- ✓ During or after exercise?

- Is a hyperglycemia pattern occurring?
- Fasting/overnight?
- ✓ After meal bolus? (1-3 hours after)
- Following hypoglycemia events?



Dottorn	Hypoglycemia	Hyperglycemia	
Pattern	Solution	Solution	
Fasting/ overnight	Recommend Sleep Schedule is set nightly. Reduce basal rates 10-20% 1-2 hours prior to hypoglycemia.	Recommend Sleep Schedule is se nightly. Increase basal rates 10-20 1-2 hours prior to hyperglycemia	
After mealtime (1-3 hours after meal boluses)	Weaken the carb ratios by 10-20% (e.g., if 1:10, change to 1:12).	Strengthen carb ratios by 10-20% (e.g., if 1:10, change to 1:8). Conside timing of bolus.	
Following high glucose	Weaken the correction factor by 10-20% (e.g., if 1:50, change to 1:55). This will impact both user-given and automatic correction boluses.	Strengthen the correction factor k 10-20% (e.g., if 1:50, change to 1:45 If unexplained hyperglycemia persists, refer to "Infusion Site Tip on next page.	
Following low glucose	Evaluate Insulin on Board. Treat extended hypoglycemia with 15g of carbs and recheck glucose in 15 minutes. Repeat as necessary.	Treat mild hypoglycemia with fewer grams of carbs (5-10g), especially after periods of reduced suspended insulin delivery.	
After a correction bolus was given (1-3 hours after)	Weaken the correction factor by 10- 20% (e.g., if 1:50 change to 1:55). Avoid overriding recommended doses.	Strengthen correction factor by 10% (e.g., if 1:50 change to 1:45).	
	Use Exercise Activity feature (timing varies based on intensity of physical activity). Consider alternate Personal Profile.	Educate on proper type, amount and timing of additional carb inta- prior to exercise.	

# Safety Goal: Reduce Hypoglycomia (<70 mg/dL) to

Content adapted with permission from the PANTHER Program,<sup>®</sup> University of Colorado, pantherprogram.org

# O4 Education

# )4 Education



## Adjustable parameters

Basal rates, carb ratios, and correction factors can be modified to patient needs. Target range values are preset to 112.5-160 mg/dL if Control-IQ technology is enabled, or modified to 112.5-120 mg/dL during Sleep Activity and 140-160 mg/dL during Exercise Activity. Correction factor directly impacts how Control-IQ technology automates insulin delivery, including bolus delivery. Studies show a more aggressive correction factor is associated with higher time in range with negligible impact to hypoglycemia.<sup>3</sup>

#### **Personal Profiles**

Up to six Personal Profiles can be created to personalize anticipated changes in insulin requirements.







## When in doubt, change it out:

- If unexplained hyperglycemia persists

   (i.e., >250 mg/dL for
   >90 minutes)
- 01 Correct by injection
- •2 Change infusion set, site, and cartridge
- OB Check for ketones



avoid s lipohyp If expending for the second second

days

 If experiencing repeated infusion site problems, try different cannula length or infusion set

## Infusion Site Tips

## Other times to change infusion set:

- If wetness (possible leaking) or redness/ swelling (possible infection) at site
- If not changed within 2-3
- If insulin or infusion set is expired
- Rotate site often to avoid scar tissue/ lipohypertrophy



### **Disconnecting:**

- If disconnecting from the pump, suspend insulin so Control-IQ technology calculates insulin on board accurately and continue to monitor glucose
- If disconnecting for 1-4 hours, deliver bolus if hyperglycemia occurs. Reduce amount for activity if neccessary.
- If disconnecting for more than four hours, have injections available as a backup plan
- Always disconnect from site on body, not the tubing connector

- D

Calculating Pump Settings				
Basal Rate	Total Daily Basal Units	Pump TDI x %Basal (40-60%) = Total Daily Basal <sup>2,4,5</sup>	$\frac{\text{UNITS/}}{\text{Pump TDI}}  \frac{\text{UNITS/}}{\text{DAY}} \times \frac{0.4-0.6}{\text{\%Basal}} = \frac{\text{UNITS/DAY}}{\text{(Total Daily Basal)}}$	
	Initial Basal Rate	Total Daily Basal ÷ 24 hours = Initial Basal Rate <sup>2,4,5</sup>	Total Daily UNITS/ 24 =UNITS/HOUR Basal DAY ÷ HOURS (Initial Basal Rate)	
Correction Factor	-	1700 <sup>†</sup> ÷ Pump TDI = Correction Factor <sup>2,4</sup>	1700 ÷ Pump TDI DAY =MG/DL:1UNIT (Correction Factor)	
Carb Ratio	-	450 ÷ Pump TDI = Carb Ratio⁵	450 ÷ Pump TDI UNITS/ =GRAMS: 1 UNIT DAY (Carb Ratio)	

<sup>†</sup>Can recalculate using 1450-2200

#### Responsible Use of Control-IQ Technology

Even with advanced systems such as the t:slim X2 insulin pump with Control-IQ technology, users are still responsible for actively managing their diabetes. Control-IQ technology does not prevent all high and low blood glucose events. The system is designed to help reduce glucose variability, but it requires that users accurately input information, such as meals and periods of sleep or exercise. Control-IQ technology will not function as intended unless all system components, including CGM, infusion sets and pump cartridges, are used as instructed. Importantly, the system cannot adjust insulin dosing if the pump is not receiving CGM readings. Because there are situations and emergencies that the system may not be capable of identifying or addressing, users should always pay attention to their symptoms and treat accordingly.

Content adapted with permission from the PANTHER Program,<sup>®</sup> University of Colorado, pantherprogram.org

\* If glucose values are predicted to be above 180 mg/dL, Control-IQ technology calculates a correction bolus using the Personal Profile settings and a target of 110 mg/dL and delivers 60% of that value.

References: 1. Diabetes Technology: Standards of Care in Diabetes - 2024. *Diabetes Care*. 2024;47(Suppl. 1):S126-S144. doi: 10.2337/dc24-S007. 2. Walsh J, Roberts R. *Pumping Insulin: Everything for Success on an Insulin Pump and CGM*. 6th ed. San Diego, CA: Torrey Pines Press; 2016. 3. Messer LH, Breton M. Therapy Settings Associated with Optimal Outcomes for t:slim X2 with Control-IQ Technology in Real World Clinical Care. *Diabetes Technol Ther*. 2023;25(12):877-882. doi: 10.1089/dia.2023.0308 4. Grunberger G, Abelseth JM, Bailey TS, et al. Consensus Statement by the American Association of Clinical Endocrinologist/American College of Endocrinology Insulin Pump Management Task Force. *Endocr Pract*. 2014;20(5):463-489. doi: 10.4158/EP14145.PS 5. Hinnen D, DeGroot J. Therapy Intensification: Technology and Pain Management. In: *The Art and Science of Diabetes Care and Education*.5th ed. Chicago: Association of Diabetes Care and Education Specialists; 2021:592-593.

Important Safety Information: RX ONLY. The t:slim X2 pump and Control-IQ technology are intended for single patient use. The t:slim X2 pump and Control-IQ technology are indicated for use with NovoLog or Humalog U-100 insulin. t:slim X2 insulin pump: The t:slim X2 insulin pump with interoperable technology is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in people requiring insulin. The pump is able to reliably and securely communicate with compatible, digitally connected devices, including automated insulin dosing software, to receive, execute, and confirm commands from these devices. The pump is indicated for use in individuals 6 years of age and greater. Control-IQ technology: Control-IQ technology is intended for use with compatible (ACE) pumps to automatically increase, decrease, and suspend delivery of basal insulin based on iCGM readings and predicted glucose values. It can also deliver correction boluses when the glucose value is predicted to exceed a predefined threshold. Control-IQ technology is intended for the management of Type 1 diabetes mellitus in persons 6 years of age and greater.

WARNING: Control-IQ technology should not be used by anyone under the age of 6 years old. It should also not be used in patients who require less than 10 units of insulin per day or who weigh less than 55 pounds.

Control-IQ technology is not indicated for use in pregnant women, people on dialysis, or critically ill patients. Do not use Control-IQ technology if using hydroxyurea. Users of the t:slim X2 pump and Control-IQ technology must: use the insulin pump, CGM, and all other system components in accordance with their respective instructions for use; test blood glucose levels as recommended by their healthcare provider; demonstrate adequate carb-counting skills; maintain sufficient diabetes self-care skills; see healthcare provider(s) regularly; and have adequate vision and/or hearing to recognize all functions of the pump, including alerts, alarms, and reminders. The t:slim X2 pump must be removed before MRI, CT, or diathermy treatment. Visit tandemdiabetes.com/safetyinfo for additional important safety information.

The **Tandem Source platform** is intended for use by individuals with diabetes mellitus who use Tandem Diabetes Care insulin pumps, their caregivers, and their healthcare providers in home and clinical settings. The Tandem Source platform supports diabetes management through the display and analysis of information uploaded from Tandem insulin pumps.

© 2024 Tandem Diabetes Care, Inc. All rights reserved. Tandem Diabetes Care, the Tandem logo, Control-IQ, Tandem Source, and t:slim X2 are either registered trademarks or trademarks of Tandem Diabetes Care, Inc. in the United States and/or other countries. All third-party marks are the property of their respective owners. ML-1012028\_C



